TY - JOUR
T1 - State-of-the-art in the pneumococcal field
T2 - Proceedings of the 11(th) International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11)
AU - ISPPD Grp
AU - Kwambana-Adams, Brenda Anna
AU - Mulholland, E. Kim
AU - Satzke, Catherine
AU - Smith-Vaughan, Heidi
AU - Brueggemann, Angela
AU - Whitney, Cynthia
AU - Kirkham, Lea-Ann
AU - Sa-Leao, Raquel
AU - Vidal, Jorge
AU - Graham, Hamish
AU - Murdoch, David
AU - Paranhos-Baccala, Glaucia
AU - Goldblatt, David
AU - Pomat, William S.
AU - Best, Emma
AU - McIntyre, Peter
AU - McVernon, Jodie
AU - Weinberger, Daniel
AU - Dunne, Eileen
AU - Scott, J. Anthony
AU - Cripps, Allan W.
AU - Mackenzie, Grant
AU - Madhi, Shabir
AU - Torzillo, Paul
AU - Graham, Steve
AU - Kartasasmita, Cissy
AU - Awori, Juliet O.
AU - Smith, Amber
AU - Hilty, Markus
AU - Blyth, Chris
AU - Pilishvili, Tamara
AU - Hammitt, Laura
AU - Andrews, Ross
AU - Crooks, Kristy
AU - Hanage, William P.
AU - Wijburg, Odilia
AU - Morpeth, Susan
AU - French, Neil
AU - Cheng, Allen
AU - Trappetti, Claudia
AU - Tuomanen, Elaine
AU - Rosch, Jason
AU - Arora, Narendra
AU - Rodgers, Gail
AU - Yoshida, Lay Myint
AU - Richmond, Peter
AU - Licciardi, Paul
AU - Ferreira, Daniela M.
PY - 2020/2/5
Y1 - 2020/2/5
N2 - The International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) is the premier global scientific symposium dedicated to the exchange, advancement and dissemination of the latest research on the pneumococcus, one of the world's deadliest bacterial pathogens. Since the first ISPPD was held in 1998, substantial progress has been made to control pneumococcal disease, for instance, more than half of surviving infants (78.6 million) from 143 countries now have access to the life-saving pneumococcal conjugate vaccine (PCV). The 11th ISPPD (ISPPD-11) was held in Melbourne, Australia in April 2018 and the proceedings of the symposium are captured in this report. Twenty years on from the first ISPPD, there remain many challenges and unanswered questions such as the continued disparity in disease incidence in Indigenous populations, the slow roll-out of PCV in some regions such as Asia, the persisting burden of disease in adults, serotype replacement and diagnosis of pneumococcal pneumonia. ISPPD-11 also put the spotlight on cutting-edge science including metagenomic, transcriptomic, microscopy, medical imaging and mathematical modelling approaches. ISPPD-11 was highly diverse, bringing together 1184 delegates from 86 countries, representing various fields including academia, primary healthcare, pharmaceuticals, biotechnology, policymakers and public health.
AB - The International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) is the premier global scientific symposium dedicated to the exchange, advancement and dissemination of the latest research on the pneumococcus, one of the world's deadliest bacterial pathogens. Since the first ISPPD was held in 1998, substantial progress has been made to control pneumococcal disease, for instance, more than half of surviving infants (78.6 million) from 143 countries now have access to the life-saving pneumococcal conjugate vaccine (PCV). The 11th ISPPD (ISPPD-11) was held in Melbourne, Australia in April 2018 and the proceedings of the symposium are captured in this report. Twenty years on from the first ISPPD, there remain many challenges and unanswered questions such as the continued disparity in disease incidence in Indigenous populations, the slow roll-out of PCV in some regions such as Asia, the persisting burden of disease in adults, serotype replacement and diagnosis of pneumococcal pneumonia. ISPPD-11 also put the spotlight on cutting-edge science including metagenomic, transcriptomic, microscopy, medical imaging and mathematical modelling approaches. ISPPD-11 was highly diverse, bringing together 1184 delegates from 86 countries, representing various fields including academia, primary healthcare, pharmaceuticals, biotechnology, policymakers and public health.
KW - Streptococcus pneumoniae
KW - Pneumonia
KW - Meningitis
KW - PCV
KW - Replacement
KW - ISPPD
KW - Asia
KW - Indigenous
KW - STREPTOCOCCUS-PNEUMONIAE
KW - CONJUGATE VACCINE
KW - OUTBREAK
KW - CHILDREN
KW - BURDEN
KW - ADULTS
KW - MICE
KW - PSPA
KW - PCPA
U2 - 10.1186/s41479-019-0064-y
DO - 10.1186/s41479-019-0064-y
M3 - Review article
C2 - 32042572
SN - 2200-6133
VL - 12
JO - Pneumonia
JF - Pneumonia
IS - 1
M1 - 2
ER -